Journey Medical (DERM)
(Delayed Data from NSDQ)
$4.83 USD
+0.32 (7.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.87 +0.04 (0.83%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DERM 4.83 +0.32(7.10%)
Will DERM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DERM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DERM
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
DERM: What are Zacks experts saying now?
Zacks Private Portfolio Services
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
Other News for DERM
Journey Medical initiated with bullish view at Rodman & Renshaw
Journey Medical Corp Q2 2024 Earnings: EPS of -$0.17 Beats Estimates, Revenue of $14. ...
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Roth MKM Issues a Buy Rating on Journey Medical Corp (DERM)
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights